NEXPLANON Drug Patent Profile

Which patents cover Nexplanon, and what generic alternatives are available?

Nexplanon is a drug marketed by Organon and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and five patent family members in thirty-five countries.

The generic ingredient in NEXPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexplanon

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NEXPLANON

International Patents:	105
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	29
Patent Applications:	2,423
Drug Prices:	Drug price information for NEXPLANON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXPLANON
What excipients (inactive ingredients) are in NEXPLANON?	NEXPLANON excipients list
DailyMed Link:	NEXPLANON at DailyMed

See drug prices for NEXPLANON

Recent Clinical Trials for NEXPLANON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oregon Health and Science University	Early Phase 1
University of Saskatchewan	Phase 2
Saskatchewan Health Authority - Regina Area	Phase 2

See all NEXPLANON clinical trials

Pharmacology for NEXPLANON

Drug Class

Progestin

Paragraph IV (Patent) Challenges for NEXPLANON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXPLANON	Implant	etonogestrel	68 mg	021529	1	2024-12-31

US Patents and Regulatory Information for NEXPLANON

NEXPLANON is protected by four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y
Organon	NEXPLANON	etonogestrel	IMPLANT;IMPLANTATION	021529-002	May 13, 2011		RX	Yes	Yes			Y

International Patents for NEXPLANON

See the table below for patents covering NEXPLANON around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	86484
Australia	2044988
Australia	603475
Canada	1309949	IMPLANT CONTRACEPTIF (CONTRACEPTIVE IMPLANT)

Supplementary Protection Certificates for NEXPLANON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0303306	SPC/GB99/044	United Kingdom		PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306	C980027	Netherlands		PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306	099C0041	Belgium		PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306	29/1999	Austria		PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825

NEXPLANON (etonogestrel implant) market dynamics and financial trajectory: revenue drivers, payer exposure, pricing pressure, and exclusivity/competition timeline

Last updated: June 11, 2026

Nexplanon (etonogestrel 68 mg subdermal contraceptive implant) is a mature, branded contraceptive with limited near-term substitute risk in the US because long-acting reversible contraception (LARC) switching has cost and clinical friction. Financial trajectory is shaped by (1) replacement-cycle demand every ~3 years, (2) market access through pharmacy benefit managers and managed care, (3) price elasticity tied to generic availability of contraceptive implants and procedure-driven care pathways, and (4) competitive pressure from branded comparator LARC devices in the same category. In the US, Nexplanon’s core revenue is tied to ongoing implant renewals rather than new prescriber adoption waves, which makes revenue more stable but less upside than growth-stage launches.

How big is the Nexplanon market and what drives revenue each year?

Nexplanon revenue is driven by implant replacement demand, not population growth alone. The implant is inserted and later removed or replaced on a cycle basis, creating recurring procurement anchored to the product’s expected dwell time (commonly ~3 years in clinical use). The largest revenue levers are patient churn within LARC cohorts and site-of-care capacity to perform insertions.

Primary revenue drivers

• Replacement-cycle volumes: Patients inserted ~3 years prior convert into new insertions, which sustains demand even when new starts slow.
• Managed care formulary placement: Rebates and net pricing effects determine affordability and utilization.
• Clinician adoption and workflow: Implant insertion requires staff training and scheduling. That slows abrupt demand shifts versus oral contraception.
• Geographic mix and contracting: Public-sector and large managed care contracts can compress net unit prices while keeping volume stable.

Secondary revenue drivers

• Adherence and discontinuation rates: Faster removals or loss to follow-up can reduce replacement-cycle capture.
• Supply continuity and procurement: Single-source branded supply can create temporary procurement dips or spikes depending on distribution performance.
• Contraceptive utilization trends: Broader shifts toward LARC or away from LARC change the addressable base but typically affect multi-year cohorts gradually.

What is the US exclusivity and patent landscape that affects Nexplanon competition?

Nexplanon is not a typical “active patent expiry to generic tablet launch” story because the commercial product is a device-delivery system coupled with a long-acting drug. Competitive dynamics hinge on whether regulators and manufacturers can file and market a legally approved equivalent and whether substitution is clinically and operationally feasible.

Core exclusivity dimensions

• Regulatory exclusivity: 505(b)(2) or NDA exclusivity, plus patent protections listed in FDA’s Orange Book for drug-substance and drug-product aspects (where applicable).
• Patent estate coverage: Methods of use (contraception regimen claims), formulation and implant composition, and manufacturing/process claims can delay full “device-like” equivalence.
• Device-analogue switching: Even with regulatory approval of an equivalent, payers may maintain prior authorization or distinct coverage tiers that affect uptake.

Practical implication for financial trajectory

• Stable replacement demand can persist through long patent tails, but net revenue can still erode through contracting and rebate renegotiations.
• If a legally approved equivalent enters, financial impact depends on payer switching behavior and clinician preference inertia.

(No Orange Book listing dates, specific patent numbers, or expiration schedules are provided in the available input. Without them, a complete and accurate exclusivity timeline cannot be produced.)

What generic or “authorized equivalent” entry risks exist for Nexplanon?

Authorized equivalent entry risk is driven by two gates: regulatory approval of an equivalent etonogestrel implant product and payer/provider acceptance. For LARC implants, even a regulatory-approved product can face slower conversion due to:

• insertion training and procurement contracts,
• patient counseling inertia,
• pharmacy purchasing structures for clinic-administered products.

Entry scenarios that typically matter financially

• Scenario A: No authorized equivalent enters
  Nexplanon’s unit volume is primarily limited by replacement-cycle demand, utilization trends, and contracting pressure. Revenue is more stable, with downside from net price.
• Scenario B: Authorized equivalent enters with payer tiering
  Expect partial share shift rather than full replacement. Net revenue can decline even if total implant volumes rise.
• Scenario C: Equivalent entry is paired with aggressive contracting
  Faster share capture occurs when managed care moves to preferred status with substantial rebate pressure.

(No company-specific generic-equivalent filings, litigation, or FDA status data are included in the provided input. A precise “when” or “who is challenging” assessment cannot be stated.)

How does Nexplanon compare with other LARC contraceptive products in market dynamics?

Nexplanon competes in the LARC contraceptive space where the decision is not purely “brand versus generic,” but also “implant versus IUD versus ring,” depending on patient and clinician preference. Financial trajectory is therefore influenced by substitution among long-acting modalities.

Category-level competitive pressure

• IUD penetration: Uptake of copper IUDs and levonorgestrel IUDs can divert patients away from implants.
• Other implants: Other contraceptive implants with distinct dosing intervals or insertion mechanics can affect share within implants.
• Service delivery model: Clinic-administered products can be sensitive to scheduling capacity and supply logistics.

Business impact

• Nexplanon can maintain demand even when growth in LARC overall is moderate because the replacement cadence and established clinician base support steady pull-through.
• Price pressure can still be significant when payers standardize preferred LARC options through formulary tiering.

What is the financial trajectory likely to look like for Nexplanon over the next 3 to 7 years?

For a mature branded LARC product, the expected financial pattern in the absence of major category disruption is:

• Volume stability from replacement-cycle pull-through,
• Net revenue growth limited by pricing, and
• Downside risk tied to contract renegotiation and any authorized-equivalent entry.

Timeline framework (conceptual)

• Near-term (12 to 24 months): Net price pressure from contracting; utilization is stable.
• Medium-term (2 to 4 years): Replacement cohorts roll forward; share impact emerges if a competitor secures preferred status.
• Long-term (4 to 7 years): Patent tail effects and any equivalent entry outcomes determine whether net price erosion becomes structural or remains contained.

(A numeric forecast requires revenue history, unit volume trends, net price data, and any regulatory or patent milestones. None are included in the provided input.)

What are the key payer, pricing, and contracting dynamics that shape Nexplanon net sales?

Nexplanon net sales are typically most exposed to:

• formulary design and rebate structures,
• utilization management in managed care,
• public payer procurement practices.

Mechanisms of net price compression

• Rebates and access incentives: Managed care can drive net price below list through formulary contracting.
• Preferred product procurement: If payers designate another LARC product as preferred, Nexplanon may face utilization declines.
• Administrative controls: Prior authorization or step therapy is less common for LARC than for oral meds but can exist through plan-specific rules.

Where revenue usually holds

• LARC is frequently viewed as cost-effective when considering pregnancy prevention and adherence. That can support coverage even when price pressure exists.

How does FDA and regulatory status affect Nexplanon’s market competitiveness?

Regulatory status affects:

• the ability of competitors to launch equivalents,
• interchangeability claims used by payers and providers, and
• labeling-driven switching behavior.

For mature contraceptive products, regulatory milestones usually matter more for competitor entry than for day-to-day Nexplanon sales, unless a major labeling change impacts use or patient eligibility.

(No current FDA labeling status details or competitor approval dates are included in the provided input.)

What patent litigation and settlement dynamics are relevant to Nexplanon business risk?

Litigation between branded and generic/authorized-equivalent entrants affects financial outcomes by:

• delaying entry, sustaining pricing,
• creating uncertainty that can prompt payers to keep branded preferred status longer, and
• influencing settlement-triggered market-entry dates.

(No Nexplanon-specific Paragraph IV, Hatch-Waxman litigation, or settlement terms are present in the provided input. A factual litigation summary cannot be produced.)

Key financial watch items for Nexplanon investors and licensors

Even without a numeric forecast, the most business-relevant indicators that determine whether revenue stays stable or erodes are:

1. Managed care contracting outcomes
   • preferred status changes
   • rebate renegotiations and net-to-gross trends
2. LARC category share shifts
   • implant share vs IUD share
3. Any regulatory approval of an authorized equivalent implant
   • approval timing and labeling comparability
4. Supply chain continuity
   • distribution disruptions that affect clinic scheduling and insertion volumes
5. Clinic adoption and protocol changes
   • training availability and procurement practices

Key Takeaways

• Nexplanon’s financial profile is primarily replacement-cycle driven, which supports steadier demand in mature periods.
• Revenue upside is typically constrained; net sales growth depends more on contracting and net pricing than on new-to-brand adoption.
• Competitive risk is structural through payer preferred-tiering and any authorized-equivalent implant entry, not through rapid switching.
• The most material near-to-medium term determinants are managed care access and whether a legally approved equivalent changes preferred status dynamics.

FAQs

1. Does Nexplanon face the same generic entry pattern as oral contraceptives?
   No; LARC implant switching is constrained by clinical workflow, procurement, and payer contracting even when regulatory comparability exists.

2. What drives Nexplanon demand most: new starts or replacements?
   Replacements tied to the expected duration of use are typically the dominant driver in mature markets.

3. How do payer formularies affect Nexplanon net pricing?
   Managed care rebates and preferred-tier contracting can materially reduce net unit revenue even when patients remain on LARC.

4. Can IUD market share changes reduce Nexplanon revenue?
   Yes, if patient choice shifts from implants to IUDs within the LARC set.

5. What is the main financial impact if an authorized equivalent implant is approved?
   Net sales often decline through preferred status migration and rebate pressure, with share effects depending on payer and clinician acceptance.

References

1. FDA Orange Book (Drug Products). U.S. Food and Drug Administration.
2. FDA Prescribing Information Database. U.S. Food and Drug Administration.

DrugChatter Q&A for NEXPLANON

How does nexplanon's wac compare in urban vs rural areas?
Nexplanon loss of exclusitivty?
Nexplanon's patent expiry?
Nexplanon patent challenge?
New exclusivity for nexplanon?